Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 non-GAAP EPS and $5.25B revenue, surpassing ...

Becton, Dickinson and Company (NYSE:BDX) Q1 2026 Earnings Call Transcript February 9, 2026 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.91, expectations were $2.81.

Medical essentials segment sales were up 0.6% (-0.6% FXN) to $1.595 billion. BioPharma Systems’ sales of $429 million were up 2.7% (+1% FXN), driven by double-digit growth in Biologics, partially ...

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXNNew BD revenue increased 2.5% FXNGAAP and adjusted diluted EPS of $1.34 and $2.91, ...

Revenue of $5.3 billion increased 1.6% as reported, 0.4% FXN New BD revenue increased 2.5% FXN GAAP and adjusted diluted EPS of $1.34 and $2.91, respectively Combination ...